Brad S. Kahl, MD

Brad S. Kahl, MD, is a professor in the John T. Milliken Department of Oncology in the Division of Oncology at the Washington University School of Medicine in St. Louis, Missouri.

Articles

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

September 8th 2023

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL

October 15th 2021

Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

Dr. Kahl on a Potential Limitation of Frontline BTK Inhibitor Combos in MCL

September 22nd 2021

Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.

Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL

September 15th 2021

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.

Dr. Kahl on the Potential for Frontline BTK Inhibitor Combinations in MCL

September 10th 2021

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

Dr. Kahl on Differences in Mechanisms of Action of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

Dr. Kahl on Remaining Challenges With CAR T-Cell Therapy in DLBCL

December 8th 2020

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL

June 12th 2020

Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.

Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14th 2017

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

x